Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus
Frontiers in Pharmacology · 19.08.2026 · 17
DOI: 10.3389/fphar.2026.1919407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.08.2026. Verfasst von Arshed Idrees und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The increasing prevalence of multidrug-resistant Staphylococcus aureus continues to compromise the effectiveness of conventional antimicrobial therapy and highlights the need for novel adjunctive treatment strategies. Despite the traditional medicinal use of Zanthoxylum species, the antibacterial potential of Zanthoxylum beecheyanum remains largely unexplored. Here, we characterized the chemical composition of Zanthoxylum beecheyanum essential oil (ZBEO) and evaluated its antibacterial activity against a panel of clinically relevant S. aureus strains, its ability to potentiate vancomycin activity, and its effects on biofilm formation. GC-MS profiling identified D-limonene and methyl cinnamate as the predominant volatile metabolites. ZBEO exhibited antibacterial activity against all tested strains, with MIC values ranging from 8 to 128 mg/L. Checkerboard assays demonstrated synergistic effects between ZBEO and vancomycin, with fractional inhibitory concentration index values as low as 0.375. Time-kill assays showed that ZBEO exhibited antibacterial activity as monotherapy and, in combination, enhanced bacterial killing and reduced bacterial regrowth compared with vancomycin alone. In addition, ZBEO inhibited biofilm formation in a concentration-dependent manner, with the greatest activity observed during combination treatment with vancomycin. Preliminary safety assessment demonstrated low hemolytic activity and limited cytotoxicity toward HEK-293 cells (CC 50 > 128 mg/L) within the antibacterial concentration range. These findings identify ZBEO as a promising adjunct to vancomycin for enhancing antibacterial activity and inhibiting S. aureus biofilm formation, warranting further investigation as a plant derived adjunctive therapy for difficult-to-treat staphylococcal infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacognosy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
- Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
- Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Zitieren
APA
Idrees, A., Abbas, I. S., Li, J., Hussein, M., & Velkov, T. (2026). Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1919407
Vancouver
Idrees A, Abbas IS, Li J, Hussein M, Velkov T. Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1919407
BibTeX
@article{Idrees2026,
author = {Idrees, Arshed and Abbas, Ibrahim Salih and Li, Jian and Hussein, Maytham and Velkov, Tony},
title = {Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1919407}
}
EUVIMED